8-K
0001883788false00018837882024-07-152024-07-150001883788dhai:PublicWarrantsMember2024-07-152024-07-150001883788us-gaap:CommonClassAMember2024-07-152024-07-15

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 15, 2024

 

 

DIH HOLDING US, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-41250

98-1624542

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

77 Accord Park Drive;

Suite D-1

 

Norwell, Massachusetts

 

02061

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 617 871-2101

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Class A Common Stock

 

DHAI

 

The Nasdaq Stock Market LLC

Warrants

 

DHAIW

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 2.02 Results of Operations and Financial Condition.

On July 15, 2024, DIH Holding US, Inc. (the “Registrant”) issued a press release announcing its fourth quarter and fiscal year ended March 31, 2024 financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On July 15, 2024, the Registrant posted an updated investor deck to its website. A copy of the updated deck is furnished as Exhibit 99.2 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(a)-(b) Financial Statements.

(c) Exhibits.

 

99.1

Release dated July 15, 2024

99.2

Updated Investor Deck dated July 15, 2024

104

Cover Page Interactive Data File (Formatted in Inline XBRL)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

DIH HOLDING US, INC.

 

 

 

 

Date:

July 15, 2024

By:

 By:/s/ Jason Chen

 

 

 

Jason Chen
Chief Executive Officer and Chairman
 

 


EX-99.1

Exhibit 99.1

DIH Announces Fiscal 2024 Fourth Quarter and Fiscal Year End Financial Results

NORWELL, MA – July 15, 2024 DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions, today announced financial results for the fiscal 2024 fourth quarter and year ended March 31, 2024.

 

Recent Highlights

 

Revenue of $64.5 million for the fiscal year ended March 31, 2024, representing growth of 19% over the prior year
Device revenue of $51.1 million and service revenue of $11.1 million for the fiscal year ended March 31, 2024, representing growth of 18% and 20%, respectively over the prior year
Positive operating cash flow of $5.2 million for the year ended March 31, 2024
Announced strategic partnership with B. Temia to enrich DIH’s rehabilitative solutions through exclusive licensing of B. Temia’s KeegoTM Dermoskeleton product in North America

 

“We are proud of our team and their excellent work over the past year,” said Jason Chen, Chairman and CEO of DIH. “Fiscal 2024 was a critical inflection year for DIH and I am encouraged by our performance. We were able to deliver significant commercial growth while simultaneously completing our initial public offering. Additionally, generating positive operating cash flow while furthering operational accomplishments creates a strong foundation for our growth strategy. With our continued industry leadership, we remain committed in our mission to build an integrated platform and consolidate the fragmented rehabilitation industry. We believe consolidation of the industry will accelerate our growth in the coming years and look forward to what fiscal 2025 will bring.”

 

Financial Results for the Fiscal Year Ended March 31, 2024

 

Revenue for the fiscal year ended March 31, 2024, was $64.5 million, an increase of $10.4 million or 19.3% compared to the prior year period. The overall increase was primarily due to an increase in devices sold of $7.7 million, or 17.7%. The increase in devices revenue was driven by higher sales volume in Europe, the Americas and Asia. Services revenue represented an increase of $1.8 million, up 19.5% compared to the prior fiscal year. Other revenues represented an increase of $0.9 million, up 70.6% compared to the prior period.

Changes in foreign currency exchange rates had a favorable impact on our net sales for the year ended March 31, 2024, resulting in an increase of approximately $1.7 million. This was mainly driven by fluctuations in Euro valuations throughout the period.

Gross profit for the fiscal year ended March 31, 2024, was $29.8 million, a decrease of 2.7% compared to the prior period. The decrease was driven by inflationary cost increases on direct costs of goods of approximately $2.2 million. The additional increase in cost of sales is mainly driven by an increase of $0.6 million in an inventory reserve for slow-moving parts and increased overhead and services parts costs of $3.9 million. The impact due to foreign currency translation losses resulted in an increase of approximately $0.1 million.

Selling, general and administrative expense for the fiscal year ended March 31, 2024, was $25.8 million, an increase of 12.3% compared to the prior period. The increase was primarily due to increase in professional service costs of $1.5 million related to audit, legal and other professional services in preparation for the business combination and becoming a publicly listed company, and investment in finance capacity in preparation for public company reporting obligations. The increase was also attributable to personnel related expenses primarily due to a $1 million increase in pension expense resulting from changes in market yields. The increase was partially offset by a decrease in credit loss provisions.


Research and development costs for the fiscal year ended March 31, 2024, were $6.6 million, a decrease of 4% compared to the prior period. The decrease was primarily due to a decrease in the research and development material purchase and external consulting of $0.2 million and charges pertaining to the Gorbel acquisition of $0.4 million, as we focus more on software developments. The decrease was offset by an increase in personnel expenses of $0.3 million.

Cash and cash equivalents at March 31, 2024 totaled $3.2 million.

 

Financial Results for the Fourth Quarter Ended March 31, 2024

 

Revenue for the three months ended March 31, 2024 was $19.4 million, a decrease of 10.2% compared to the prior year period. The decrease was due primarily to alignment with customer schedules for order fulfillment, which resulted in a $2.9 million decrease in device revenue. The Company expects to recognize the revenues related to these products in fiscal year 2025.

Changes in foreign currency exchange rates had a minor favorable impact on our net sales in the three months ended March 31, 2024, resulting in an increase of approximately $0.1 million. This was driven by stabilization of Euro valuations.

Gross profit for the three months ended March 31, 2024 was $9.8 million, a 33.8% decrease compared to the prior period. The decrease was primarily due to the timing of revenue recognition related to customer-driven installation delays, inflationary cost increases on direct costs of goods, and increased overhead and services parts costs.

Selling, general and administrative expense for the three months ended March 31, 2024, was $8.1 million, an increase of 19.2% compared to the prior period. The increase was primarily due to increased overhead expense of $1.5 million primarily related to additional IT consultancy expenses and software license costs, as well as an increase in insurance expenses pertaining to the close of the business combination. The increase was offset by a decrease of professional service cost during the three months ended March 31, 2024, related to audit, legal and professional service.

Research and development costs for the three months ended March 31, 2024, were $1.9 million, a decrease of 2.5% compared to the prior period. The prior period had included charges pertaining to the Gorbel acquisition of $0.1 million with no similar expense in the three months ended March 31, 2023.

Subsequent Events

 

On June 6, 2024, the Company entered into a Securities Purchase Agreement, pursuant to which the Company issued $3.3 million in principal amount of 8% Original Issue Discount Senior Secured Convertible Debentures (the “Debentures”). The Debentures were issued with an original issue discount of $300 thousand, resulting in gross proceeds of approximately $3 million and net proceeds of approximately $2.5 million after deducting estimated offering expenses.

The Debentures are convertible into an aggregate of 660,000 shares of the Company’s Class A Common Stock at a conversion price of $5.00 per share, subject to adjustment. The Debentures mature on December 7, 2025, and bear interest at a rate of 8% per annum, payable monthly beginning one year from the issuance date.

Provided that no event of default has occurred or is continuing, and at least 33% of the principal amount of the Debentures has either previously been repaid or converted in accordance with the terms of the Debenture, the Company may elect, by notice to the holder of the Debentures, to extend the Maturity Date by six months upon the payment of six months’ interest on the then-outstanding principal amount.

The Debentures are secured by substantially all of the assets of the Company and its domestic subsidiaries, excluding certain specified assets. Additionally, the Company’s domestic subsidiaries have provided an unconditional guarantee of the Debentures. In connection with the issuance of the Debentures, the Company also issued warrants to purchase an aggregate of 330,000 shares of Class A Common Stock at an exercise price of $5.00 per share, with a five-year term.


Fiscal Year 2025 Outlook

The Company expects gross revenue for fiscal year 2025 to range between $74 million and $77 million, representing approximately 15%-20% growth over fiscal year 2024.

About DIH Holding US, Inc.

DIH stands for the vision to “Deliver Inspiration & Health” to improve the daily lives of millions of people with disabilities and functional impairments through providing devices and solutions enabling intensive rehabilitation. DIH is a global provider of advanced robotic devices that incorporate virtual reality technologies (“VR”) to enable research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Built through the mergers of global-leading niche technology providers, DIH is positioning itself as a transformative rehabilitation solutions provider and consolidator of a largely fragmented and manual-labor-driven industry.

Caution Regarding Forward-Looking Statements

This press release contains certain statements which are not historical facts, which are forward-looking statements within the meaning of the federal securities laws, for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These forward-looking statements include certain statements made with respect to the business combination, the services offered by DIH and the markets in which it operates, and DIH’s projected future results. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions provided for illustrative purposes only, and projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These risks and uncertainties include, but are not limited to: general economic, political and business conditions; the ability of DIH to achieve its projected revenue, the failure of DIH realize the anticipated benefits of the recently-completed business combination and access to sources of additional debt or equity capital if needed. While DIH may elect to update these forward-looking statements at some point in the future, DIH specifically disclaims any obligation to do so.

 

Investor Contact
Greg Chodaczek
332-895-3230

Investor.relations@dih.com

 


DIH HOLDING US, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data, unaudited)

 

 

 

March 31,

 

 

 

2024

 

 

2023

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

3,225

 

 

$

3,175

 

Accounts receivable, net of allowances of $667 and $1,683, respectively

 

 

5,197

 

 

 

5,998

 

Inventories, net

 

 

7,830

 

 

 

4,850

 

Due from related party

 

 

5,688

 

 

 

6,383

 

Other current assets

 

 

5,116

 

 

 

4,855

 

Total current assets

 

 

27,056

 

 

 

25,261

 

Property, and equipment, net

 

 

530

 

 

 

742

 

Capitalized software, net

 

 

2,131

 

 

 

2,019

 

Other intangible assets, net

 

 

380

 

 

 

380

 

Operating lease, right-of-use assets, net

 

 

4,466

 

 

 

2,604

 

Other tax assets

 

 

267

 

 

 

1

 

Other assets

 

 

905

 

 

 

772

 

Total assets

 

$

35,735

 

 

$

31,779

 

Liabilities and Deficit

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

4,305

 

 

$

2,190

 

Employee compensation

 

 

2,664

 

 

 

3,163

 

Due to related party

 

 

10,192

 

 

 

6,841

 

Current portion of deferred revenue

 

 

5,211

 

 

 

7,714

 

Manufacturing warranty obligation

 

 

513

 

 

 

973

 

Current portion of long-term operating lease

 

 

1,572

 

 

 

1,005

 

Advance payments from customers

 

 

10,562

 

 

 

6,255

 

Accrued expenses and other current liabilities

 

 

9,935

 

 

 

8,631

 

Total current liabilities

 

 

44,954

 

 

 

36,772

 

Notes payable - related party

 

 

11,457

 

 

 

17,301

 

Non-current deferred revenues

 

 

4,670

 

 

 

2,282

 

Long-term operating lease

 

 

2,917

 

 

 

1,621

 

Deferred tax liabilities

 

 

112

 

 

 

110

 

Other non-current liabilities

 

 

4,171

 

 

 

2,647

 

Total liabilities

 

$

68,281

 

 

$

60,733

 

Commitments and contingencies

 

 

 

 

 

 

Deficit:

 

 

 

 

 

 

Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2024; no shares authorized, issued and outstanding at March 31, 2023

 

 

 

 

 

 

Common stock, $0.0001 par value; 100,000,000 shares authorized; 34,544,935 shares issued and outstanding at March 31, 2024; 25,000,000 shares authorized, issued and outstanding at March 31, 2023

 

 

3

 

 

 

2

 

Additional paid-in-capital

 

 

2,613

 

 

 

(1,898

)

Accumulated deficit

 

 

(35,212

)

 

 

(26,769

)

Accumulated other comprehensive income (loss)

 

 

50

 

 

 

(289

)

Total deficit

 

$

(32,546

)

 

$

(28,954

)

Total liabilities and deficit

 

$

35,735

 

 

$

31,779

 

 


DIH HOLDING US, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data, unaudited)

 

Three Months Ended March 31,

 

 

Years Ended March 31,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Revenue

 

$

19,356

 

 

$

21,556

 

 

$

64,473

 

 

$

54,059

 

Cost of sales

 

 

9,547

 

 

 

6,742

 

 

 

34,702

 

 

 

23,474

 

Gross profit

 

 

9,809

 

 

 

14,814

 

 

 

29,771

 

 

 

30,585

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general, and administrative expense

 

 

8,124

 

 

 

6,813

 

 

 

25,776

 

 

 

22,957

 

Research and development

 

 

1,928

 

 

 

1,977

 

 

 

6,609

 

 

 

6,919

 

Total operating expenses

 

 

10,052

 

 

 

8,790

 

 

 

32,385

 

 

 

29,876

 

Operating income (loss)

 

 

(243

)

 

 

6,024

 

 

 

(2,614

)

 

 

709

 

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Interest (expense)

 

 

(232

)

 

 

(117

)

 

 

(693

)

 

 

(277

)

Other income (expense), net

 

 

(3,709

)

 

 

27

 

 

 

(3,890

)

 

 

572

 

Total other income (expense)

 

 

(3,941

)

 

 

(90

)

 

 

(4,583

)

 

 

295

 

Income (loss) before income taxes

 

 

(4,184

)

 

 

5,934

 

 

 

(7,197

)

 

 

1,004

 

Income tax expense (benefit)

 

 

587

 

 

 

1,255

 

 

 

1,246

 

 

 

2,018

 

Net Income (loss)

 

$

(4,771

)

 

$

4,679

 

 

$

(8,443

)

 

$

(1,014

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net earnings (loss) per share, basic and diluted

 

$

(0.16

)

 

$

0.19

 

 

$

(0.32

)

 

$

(0.04

)

Weighted-average shares outstanding, basic and diluted

 

 

30,559

 

 

 

25,000

 

 

 

26,382

 

 

 

25,000

 

 


DIH HOLDING US, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(in thousands, unaudited)

 

 

Three Months Ended March 31,

 

Years Ended March 31,

 

 

 

2024

 

2023

 

2024

 

2023

 

Net income (loss)

 

$

(4,771

)

 

$

4,679

 

$

(8,443

)

 

$

(1,014

)

Other comprehensive (loss) income, net of tax

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustments, net of tax of $0

 

 

627

 

 

 

(282

)

 

1,455

 

 

 

(503

)

Pension liability adjustments, net of tax of $0

 

 

(100

)

 

 

(230

)

 

(1,116

)

 

 

(421

)

Other comprehensive (loss) income

 

 

(924

)

 

 

(512

)

 

339

 

 

 

(924

)

Comprehensive loss

 

$

(1,938

)

 

$

4,167

 

$

(8,104

)

 

$

(1,938

)

 


DIH HOLDING US, INC. AND SUBSIDIARIES

INTERIM CONDENSED COMBINED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)

(in thousands, unaudited)

 

Common Stock

 

 

 

 

 

 

 

 

 

 

Shares(1)

 

Amount

 

Additional Paid-In Capital

 

Accumulated Deficit

 

Accumulated Other Comprehensive Income (Loss)

 

Total Equity (Deficit)

 

Balance, March 31, 2022

 

25,000,000

 

$

2

 

$

(1,776

)

$

(25,755

)

$

635

 

$

(26,894

)

Net loss

 

 

 

 

 

 

 

(1,014

)

 

 

 

(1,014

)

Other comprehensive loss, net of tax

 

 

 

 

 

 

 

 

 

(924

)

 

(924

)

Net transactions with DIH Cayman

 

 

 

 

 

(122

)

 

 

 

 

 

(122

)

Balance, March 31, 2023

 

25,000,000

 

$

2

 

$

(1,898

)

$

(26,769

)

$

(289

)

$

(28,954

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

 

(8,443

)

 

 

 

(8,443

)

Issuance of common stock upon reverse recapitalization

 

9,544,935

 

 

1

 

 

4,511

 

 

 

 

 

 

4,512

 

Other comprehensive income, net of tax

 

 

 

 

 

 

 

 

 

339

 

 

339

 

Balance, March 31, 2024

 

34,544,935

 

$

3

 

$

2,613

 

$

(35,212

)

$

50

 

$

(32,546

)

 

 


DIH HOLDING US, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands, unaudited)

 

 

Years Ended March 31,

 

 

 

2024

 

 

2023

 

Cash flows from operating activities:

 

 

 

 

 

 

Net loss

 

$

(8,443

)

 

$

(1,014

)

Adjustments to reconcile net loss to net cash provided by operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

302

 

 

 

66

 

Provision for credit losses

 

 

(1,016

)

 

 

669

 

Allowance for inventory obsolescence

 

 

617

 

 

 

(1,639

)

Noncash business combination expense

 

 

3,514

 

 

 

-

 

Pension contributions

 

 

(530

)

 

 

(569

)

Pension (income) expense

 

 

(75

)

 

 

(400

)

Foreign exchange (gain) loss

 

 

376

 

 

 

(584

)

Noncash lease expense

 

 

1,590

 

 

 

1,423

 

Noncash interest expense

 

 

28

 

 

 

19

 

Change in manufacturing warranty obligation estimate

 

 

(626

)

 

 

 

Deferred and other noncash income tax expense

 

 

(304

)

 

 

58

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

1,853

 

 

 

(514

)

Inventories

 

 

(3,259

)

 

 

518

 

Due from related parties

 

 

1,018

 

 

 

(969

)

Due to related parties

 

 

3,337

 

 

 

2,471

 

Other assets

 

 

(229

)

 

 

(1,805

)

Operating lease liabilities

 

 

(1,782

)

 

 

(1,448

)

Accounts payable

 

 

2,920

 

 

 

38

 

Employee compensation

 

 

(551

)

 

 

(151

)

Other liabilities

 

 

970

 

 

 

(96

)

Deferred revenue

 

 

(90

)

 

 

4,059

 

Manufacturing warranty obligation

 

 

163

 

 

 

160

 

Advance payments from customers

 

 

4,338

 

 

 

2,083

 

Accrued expense and other current liabilities

 

 

1,071

 

 

 

3,126

 

Net cash provided by operating activities

 

 

5,192

 

 

 

5,501

 

Cash flows from investing activities:

 

 

 

 

 

 

Purchases of property and equipment

 

 

(202

)

 

 

(145

)

Net cash used in investing activities

 

 

(202

)

 

 

(145

)

Cash flows from financing activities:

 

 

 

 

 

 

Proceeds from reverse recapitalization

 

 

899

 

 

 

 

Payments on related party notes payable

 

 

(5,844

)

 

 

(4,053

)

Net cash used in financing activities

 

 

(4,945

)

 

 

(4,053

)

Effect of currency translation on cash and cash equivalents

 

 

5

 

 

 

(61

)

Net increase in cash, and cash equivalents, and restricted cash

 

 

50

 

 

 

1,242

 

Cash, and cash equivalents, and restricted cash - beginning of year

 

 

3,175

 

 

 

1,933

 

Cash, and cash equivalents, and restricted cash - end of year

 

$

3,225

 

 

$

3,175

 

Cash and cash equivalents - end of year

 

$

3,225

 

 

$

3,175

 

Restricted cash - end of year

 

 

 

 

 

 

Total cash, and cash equivalents, and restricted cash - end of year

 

$

3,225

 

 

$

3,175

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

Interest paid

 

$

665

 

 

$

258

 

Income tax paid

 

$

 

 

$

210

 

Supplemental disclosure of non-cash investing and financing activity:

 

 

 

 

 

 

Accrued liability related to asset acquisition

 

$

 

 

$

533

 

Accounts payable settled through escrow account upon reverse recapitalization

$

1,439

 

 

$

 


Slide 1

DELIVER INSPIRATION & HEALTH DELIVER INSPIRATION & HEALTH DIH DEDICATED TO RESTORING MOBILITY AND ENHANCING HUMAN PERFORMANCE Investor Presentation July 2024 Nasdaq: DHAI


Slide 2

DELIVER INSPIRATION & HEALTH In this presentation, “DIH”, the “Company”, “we”, “us” and “our” mean DIH Holding US, Inc, a Delaware corporation (Nasdaq: DHAI). All amounts are in U.S. dollars unless otherwise indicated. The information contained herein does not purport to contain all of the information about the Company. The information contained herein has not been independently verified. No representations or warranties are made or implied with respect to the information contained herein. This presentation contains forward-looking statements with respect to the Company. These forward-looking statements, by their nature, require the Company to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements, including without limitation the successful and timely completion and the commercialization of the products referred to herein. Forward-looking statements are not guarantees of performance. These forward-looking statements, including financial outlooks and strategies or deliverables stated herein, may involve, but are not limited to, comments with respect to the Company’s business or financial objectives, its strategies or future actions, its targets, expectations for financial condition or outlook for operations. Words such as “may”, “will”, “would”, “could”, “expect”, “believe”, “plan”, “anticipate”, “intend”, “estimate”, “continue”, or the negative or comparable terminology, as well as terms usually used in the future and conditional, are intended to identify forward-looking statements. Information contained in forward-looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including perceptions of historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. These assumptions are considered to be reasonable based on currently available information, but the reader is cautioned that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company and its business. The forward-looking information set forth therein reflects expectations as of the date hereof and is subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Undue reliance should not be placed on forward-looking statements. The forward-looking statements contained in this presentation are expressly qualified by this cautionary statement. This presentation is not intended to form the basis of any investment decision and there can be no assurance that any transaction will be undertaken or completed in whole or in part. The delivery of this presentation shall not be taken as any form of commitment on the part of the Company or its stockholders to proceed with any transaction, and no offers will subject the Company or its stockholders to any contractual obligations before definitive documentation has been executed. The Company reserves the right at any time without prior notice and without any liability to (i) negotiate with one or more prospective investors in accordance with any timetable and on any terms that the Company may decide, (ii) provide different information or access to information to different prospective investors, (iii) enter into definitive documentation and (iv) terminate the process, including any negotiations with any prospective investor without giving any reasons therefor. INVESTOR PRESENTATION Page 2


Slide 3

DELIVER INSPIRATION & HEALTH DELIVER INSPIRATION & HEALTH DIH at a glance: Robotic-enabled movement platform improving the lives of people with disabilities and functional impairments


Slide 4

INVESTOR PRESENTATION Improving lives by providing human movement therapy while empowering leading scientists and clinics to study balance and movement disorders through Advanced Technology. DELIVER INSPIRATION & HEALTH


Slide 5

INVESTOR PRESENTATION DIH – a Global Solution Provider, has the broadest portfolio in neuro-rehabilitation and human performance research, with over 4,500 devices installed. With an aging population and an increasing number of people living with neurological diseases, hospitals and clinics will be understaffed; robotic rehabilitation fills the gap and helps therapists and patients thrive. More intensive, repetition-based therapy, supported by Advanced Technology is shown to have superior patient outcomes and can send them home sooner. Technology solves the supply-demand problem in rehabilitation settings by allowing occupational and physical therapists to work with multiple patients effectively. Bridges the gap between Clinical and Research applications by enabling and inventing the most advanced technological ways to study and treat balance and movement disorders. DELIVER INSPIRATION & HEALTH


Slide 6

INVESTOR PRESENTATION 19 Products & Systems $64.5M FY242 Revenue 19% YoY increase 5 Commercial Regions USA, Singapore, Chile, Slovenia, Germany 243 Employees in 9 global locations from 33 nationalities ` 4,500+ Devices installed1 1,500+ Medical device registrations in 75 countries Sites 3 For R&D and manufacturing in CH,NL and USA 1,800 Customer Accounts 1 HQ DIH Holding US $74M - $77M FY25 Revenue Guidance 17% YoY increase3 DELIVER INSPIRATION & HEALTH 1 Includes clinical and research install base 2 FY24 year ending March 31, 2024 3 FY25 YoY revenue growth at the midpoint of guidance


Slide 7

DELIVER INSPIRATION & HEALTH DELIVER INSPIRATION & HEALTH Meeting market demands with innovative Advanced Technologies


Slide 8

Patients Neurological Stroke SCI & cerebral palsy Parkinson’s disease Traumatic brain injury Orthopedic Amputation Osteoarthritis Musculoskeletal disorders Geriatric & Pediatric Aging population with an increased risk of falling and functional impairment Pediatric patients with mobility impairments Health Providers Rehabilitation Hospitals Research Facilities INVESTOR PRESENTATION Physical Therapy and Rehab Clinics DELIVER INSPIRATION & HEALTH


Slide 9

INVESTOR PRESENTATION Research & Human Movement Labs* (“Research Market”) CAREN DOME CAREN EXTENDED GRAIL M-GAIT 1 Two product lines available 2 Product line consists of three products 3 Prototype available; In development . *Motek products are currently being sold by DIH through an exclusive relationship between Motek and DIH Rehabilitation Hospitals and Outpatient Clinics (“Hospital and Clinic Market”) ARM & HAND ARMEO POWER ARMEO SPRING / SPRING PRO ARMEO SENSO GAIT & BALANCE ERIGO1 LOKOMAT 1 SAFEGAIT1 RYSEN ANDAGO C-MILL2 3 DATA INTEGRATION DELIVER INSPIRATION & HEALTH


Slide 10

INVESTOR PRESENTATION Aging population Advanced Technology is key to meeting market demands. Increasing neurological disorders and related disabilities Need of care and lack of therapist 1 “Ageing and Health.” World Health Organization, World Health Organization, www.who.int/news-room/fact-sheets/detail/ageing-and- health. Accessed 22 Feb. 2024. 2 “Ageing and Disability Enable.” United Nations, United Nations, www.un.org/development/desa/disabilities/disability-and-ageing.html. Accessed 22 Feb. 2024. 3 Feigin, Valery L., et al. "Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016." The Lancet Neurology 18.5 (2019): 459-480. 4 “Stroke, Cerebrovascular Accident.” World Health Organization, World Health Organization, www.emro.who.int/health-topics/stroke- cerebrovascular-accident/index.html. Accessed 22 Feb. 2024. DELIVER INSPIRATION & HEALTH 5 Cieza, Alarcos, et al. "Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019." The Lancet 396.10267 (2020): 2006-2017. 6 World Physiotherapy 2020, world.physio/sites/default/files/2021-02/AMC2020-Europe.pdf. Accessed 22 Feb. 2024. “Indicator Metadata Registry Details.” World Health Organization, World Health Organization, www.who.int/data/gho/indicator-metadata- registry/imr-details/3408. Accessed 22 Feb. 2024. LLC, Globalen. “Physiotherapists per 1,000 People by Country, around the World.” TheGlobalEconomy.Com, www.theglobaleconomy.com/rankings/physiotherapists_per_1000_people/%C2%A0. Accessed 22 Feb. 2024. ≈50% of stroke survivors are left with disabilities4 >1B Members of a growing elderly population, worldwide1 > 46% of the world's aging population has disabilities2 Est. 1.09 physiotherapists per 1,000 people6 2.41B People are currently living with a health condition that may benefit from rehabilitation5 Est.15% of the global population is affected by neurological disorders3


Slide 11

INVESTOR PRESENTATION ROBOTIC ARM MOVEMENT SUPPORT TRAINING PATIENT ABILITY (MMT) MMT 0 MMT 1 MMT 2 MMT 3 MMT 4 MMT 5 ARM WEIGHT SUPPORT TRAINING PATIENT NEEDS SELF-DIRECTED TRAINING MMT: Manual Muscle Test for shoulder and/or elbow; MMT 2 for Armeo Senso =with arm weight support DELIVER INSPIRATION & HEALTH


Slide 12

PATIENT ABILITY (FAC) INVESTOR PRESENTATION FAC 0 FAC 1 FAC 2 FAC 3 FAC 4 FAC 5 MOBILIZATION AND VERTICALIZATION FAC: Functional Ambulation categories * Available only in the USA DELIVER INSPIRATION & HEALTH REPETITIVE, PHYSIOLOGICAL GAIT TRAINING OVERGROUND GAIT AND BALANCE TRAINING OVERGROUND BODY WEIGHT SUPPORT PATIENT NEEDS GAIT ADAPTABILITY TRAINING


Slide 13

DELIVER INSPIRATION & HEALTH INVESTOR PRESENTATION Page 13 Modular Gait Lab TARGETS ALL ASPECTS OF BALANCE AND LOCOMOTION. THE USE OF VIRTUAL REALITY ENABLES RESEARCHERS TO ASSESS THE SUBJECT’S BEHAVIOR AND INCLUDES SENSORY INPUTS LIKE VISUAL, AUDITORY AND VESTIBULAR. PROVIDES ANALYSIS AND THERAPY IN CHALLENGING CONDITIONS TO IMPROVE GAIT, WHILE REAL-TIME FEEDBACK ENABLES ANALYSIS AND TRAINING DURING THE SAME SESSION. ENABLES MULTIPLE SYSTEM ENHANCEMENTS FOR ADDED FUNCTIONALITY OF GAIT-LAB. INTENDED USE Gait Real-time Analysis Interactive Lab Computer Assisted Rehabilitation Environment Computer Assisted Rehabilitation Environment *Motek products are currently being sold by DIH through an exclusive relationship between Motek and DIH


Slide 14

INVESTOR PRESENTATION We provide guidelines and support customers in building their rehabilitation project. We find the right solution to match the organizations’ needs, space and budget. BUSINESS MODEL and PLANNING To help make the best use of our solutions, we offer clinical integration consulting and ongoing support, as well as education and training. CLINICAL SERVICES We provide technical support and regular maintenance after installation so customers can maintain clinical routines without disruption. TECHNICAL SERVICES Research drives us forward and our support and services help institutions initiate their own research programs. RESEARCH SERVICES Customers immediately stand out from other rehabilitation facilities. With our support we make sure they are seen and heard. MARKETING SERVICES DIH provides a broad portfolio of devices and an extensive range of services, to become a Total Solution partner for our customers DELIVER INSPIRATION & HEALTH


Slide 15

INVESTOR PRESENTATION DIH collaborates with world renowned institutions in rehabilitation and research as reference centers and innovation partners DELIVER INSPIRATION & HEALTH


Slide 16

C-Mill 70* GRAIL & M-Gait 234* INVESTOR PRESENTATION 1The Knowledge Platform includes all research articles, conference proceedings, and theses available on our devices and can be accessed via knowledge.hocoma.com and knowledge.motekmedical.com 2 Reviewed and evaluated by a group of experts in the field before the article is published. *Motek Products are currently being sold by DIH through an exclusive relationship between Motek and DIH LOKOMAT 610 ARMEO LINE 217 ERIGO 60 CAREN 204* >1,000 publications in peer-reviewed2 journals 40+ ongoing studies DELIVER INSPIRATION & HEALTH


Slide 17

Early Entrants Emerging Players Industry Leader DIH is uniquely positioned as a leader in rehabilitation-tech and research markets INVESTOR PRESENTATION LFWD (NASDAQ) EKSO (NASDAQ) DVL (ASX) DHAI (NASDAQ) DELIVER INSPIRATION & HEALTH


Slide 18

INVESTOR PRESENTATION Leading Technology Highly recognized premier brands and technologies in our industry, endorsed by leading rehabilitation institutes and opinion leaders Product Portfolio Broadest product portfolio in advanced robotics and sophisticated VR-enabled movement systems; most competitors operate in a single product category Commercial Reach Strong global market coverage with approx. 3-5x more sales volume than competitors Innovation Sustained innovation capabilities with decades of proven expertise and resources Tech Partnerships Platform and core technology (hardware and software) supported by strong partnerships with leading research groups Network Effect Strong supporting functions and operational infrastructure that establish a platform network effect which will be difficult to replicate Industry Experience Organizational breadth and depth with significant experience in acquisition integration; key to our growth strategy and differentiation from competitors that are early in their organizational life cycles DELIVER INSPIRATION & HEALTH


Slide 19

Global solution provider combining innovative robotic and VR technologies with clinical integration and proprietary insights. entire FY24, Transformative total solutions provider and consolidator in a fragmented and manual-labor-driven industry. Innovative and broad product portfolio, covering the continuum of care. Strong growth opportunity with $64.5M revenue in representing 19% year-over-year growth. INVESTOR PRESENTATION $14.9B1 Total global rehabilitation equipment market DELIVER INSPIRATION & HEALTH ~$590M1 Rehabilitation Robots Market ~27%1 Estimated market CAGR through 2027 1 “Rehabilitation Robots Market by Product, End user and Geography – Forecast and Analysis (2023 – 2027)” November 2022 Global Market


Slide 20

DELIVER INSPIRATION & HEALTH DELIVER INSPIRATION & HEALTH Way Forward - Investment Opportunity


Slide 21

High manual therapies costs are primed for disruption across care centers Robotic solutions provide value and save costs, creating flexibility within institutional budgets INVESTOR PRESENTATION Rehab Hospitals Long-Term Care & Skilled Nursing Facilities Outpatient Clinics Acute Rehab $50B in manual therapies costs1 DELIVER INSPIRATION & HEALTH 1 Grandview Research, October 14, 2022


Slide 22

Phase 3 Phase 2 Penetrate Markets Drive Market Standardization Develop Total Solutions Expand presence in US and EU Prioritize product innovation and integration efforts Enter new institutions Further penetrate existing accounts Leverage global platforms and infrastructure Realize economies of scale Execute strong M&A targeting Provide fully supported product ecosystems Create significant value and cost savings for providers Enhance the therapy business model Phase 1 INVESTOR PRESENTATION DELIVER INSPIRATION & HEALTH


Slide 23

DELIVER INSPIRATION & HEALTH DELIVER INSPIRATION & HEALTH Financial Highlights


Slide 24

$54.1M $64.5M $75.5M* 0 10 20 30 40 50 60 70 80 Revenue Dollars ($M) Fiscal Year 2023 Fiscal Year 2024 Fiscal Year 2025e INVESTOR PRESENTATION $64.5M Revenue, +19% YoY growth 79% devices 17% services 4% other $(8.4M) Net Loss 46% Gross Margin $5.2M Cash Flow from Operations Fiscal Year 2024 $74.0M - $77.0M Fiscal Year 2025 Revenue Guidance 19% YoY Growth 17% YoY Growth* DELIVER INSPIRATION & HEALTH *FY25 YoY revenue growth at midpoint of guidance


Slide 25

INVESTOR PRESENTATION Jason Chen Chief Executive Officer and Chairman of the Board Lynden Bass Chief Financial Officer Dr. Patrick Bruno Chief Market Officer DELIVER INSPIRATION & HEALTH


Slide 26

INVESTOR PRESENTATION CEO and Chairman of the Board Jason Chen Chief Financial Officer Lynden Bass Chief Market Officer Hospital & Clinic Patrick Bruno Senior Vice President Sales – EMEA Indirect Slavko Skafar Vice President Global Operations Walther Geiger Vice President FP&A and Commercial Operations Finance LaTonya Vincent Vice President Research Frans Steenbrink DELIVER INSPIRATION & HEALTH


Slide 27

DELIVER INSPIRATION & HEALTH DELIVER INSPIRATION & HEALTH THANK YOU For more information contact investor.relations@dih.com